INS and cancer: SGK1 is activated by insulin, growth factors, and steroids – this may explain the increased cancer risk for patients with obesity and insulin resistance29, as well as explain the dual activity of metformin (which we hypothesize to act as an inhibitor of SGK1) in diabetics as well as cancer patients.